RNAi-based therapeutics and tumor targeted delivery in cancer
Over the past decade, non-coding RNA-based therapeutics have proven as a great potential
for the development of targeted therapies for cancer and other diseases. The discovery of …
for the development of targeted therapies for cancer and other diseases. The discovery of …
siRNA: Mechanism of action, challenges, and therapeutic approaches
W Alshaer, H Zureigat, A Al Karaki, A Al-Kadash… - European journal of …, 2021 - Elsevier
Owing to specific and compelling gene silencing, RNA interference (RNAi) is expected to
become an essential approach in treating a variety of infectious, hemato-oncological …
become an essential approach in treating a variety of infectious, hemato-oncological …
[HTML][HTML] Current advances in RNA therapeutics for human diseases
H Zogg, R Singh, S Ro - International journal of molecular sciences, 2022 - mdpi.com
Following the discovery of nucleic acids by Friedrich Miescher in 1868, DNA and RNA were
recognized as the genetic code containing the necessary information for proper cell …
recognized as the genetic code containing the necessary information for proper cell …
Paving the road for RNA therapeutics
N Dammes, D Peer - Trends in pharmacological sciences, 2020 - cell.com
Therapeutic RNA molecules possess high potential for treating medical conditions if they
can successfully reach the target cell upon administration. However, unmodified RNA …
can successfully reach the target cell upon administration. However, unmodified RNA …
Phosphorothioate modified oligonucleotide–protein interactions
Antisense oligonucleotides (ASOs) interact with target RNAs via hybridization to modulate
gene expression through different mechanisms. ASO therapeutics are chemically modified …
gene expression through different mechanisms. ASO therapeutics are chemically modified …
Message in a bubble: shuttling small RNAs and proteins between cells and interacting organisms using extracellular vesicles
Q Cai, B He, S Wang, S Fletcher, D Niu… - Annual review of …, 2021 - annualreviews.org
Communication between plant cells and interacting microorganisms requires the secretion
and uptake of functional molecules to and from the extracellular environment and is …
and uptake of functional molecules to and from the extracellular environment and is …
Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics
Cancer, infectious diseases, and metabolic and hereditary genetic disorders are a global
health burden affecting millions of people, with contemporary treatments offering limited …
health burden affecting millions of people, with contemporary treatments offering limited …
[HTML][HTML] Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic “dark matter”
The discovery of the role of non-coding RNAs (ncRNAs) in the onset and progression of
malignancies is a promising frontier of cancer genetics. It is clear that ncRNAs are …
malignancies is a promising frontier of cancer genetics. It is clear that ncRNAs are …
[HTML][HTML] MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives
Background Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disease ranging from
simple hepatic steatosis (NAFL) to non-alcoholic steatohepatitis (NASH) which may …
simple hepatic steatosis (NAFL) to non-alcoholic steatohepatitis (NASH) which may …
[HTML][HTML] The challenges and strategies of antisense oligonucleotide drug delivery
M Gagliardi, AT Ashizawa - Biomedicines, 2021 - mdpi.com
Antisense oligonucleotides (ASOs) are used to selectively inhibit the translation of disease-
associated genes via Ribonuclease H (RNaseH)-mediated cleavage or steric hindrance …
associated genes via Ribonuclease H (RNaseH)-mediated cleavage or steric hindrance …